Purpose The efficacy of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) in patients with chronic kidney disease (CKD) remains unclear. The aim of this meta-analysis is to explore the association between ICD/ CRT and mortality in CKD patients. Methods An electronic search was conducted using MEDLINE. We included studies that reported outcomes of interest in CKD patients stratified by the presence of ICD, CRT, or none. The primary outcome was all-cause mortality. Outcomes were pooled using random effects model. Odds ratios (OR) were reported for dichotomous variables. Results The literature search resulted in 11 studies (observational studies) including 21,136 adult patients: seven studies compared ICD vs. no ICD and four studies compared CRT vs. ICD. All-cause mortality was significantly lower in the ICD group in comparison to that in the no ICD group (OR 0.66 (95% confidence interval [CI] 0.45; 0.98), P = 0.04). Among dialysis-only patients, all-cause mortality was significantly lower in the ICD group (OR 0.49 (95% CI 0.38; 0.64), P < 0.001). All-cause mortality was significantly lower in the CRT group in comparison to that in the ICD group (OR 0.73 (95% CI 0.57; 0.92), P = 0.01). Conclusions The use of ICDs is associated with lower all-cause mortality in observational studies of CKD patients. CRT use was also associated with lower all-cause mortality in CKD patients in comparison to ICDs. A randomized controlled trial is required to definitively define the role of ICDs/CRTs in CKD patients.
Introduction
Chronic kidney disease (CKD) is associated with increased cardiovascular mortality, particularly from sudden cardiac death (SCD). The highest rate of SCD is seen in patients with endstage renal disease (ESRD). SCD might be responsible for 60% of cardiac deaths in patients undergoing dialysis [1, 2] .
Although the cardiovascular risk increases sharply as the glomerular filtration rate (GFR) declines [3] , mild-moderate renal impairment represents an established risk factor for cardiovascular disease and mortality. This risk is independent of other known risk factors, such as hypertension or diabetes [4, 5] .
The benefit of ICDs and CRTs in primary and secondary prevention of SCD is well established in the general population with cardiovascular disease [6] [7] [8] .
Most of the cardiovascular clinical trials including those of ICD and CRT studies excluded patients with advanced CKD [9, 10] . More so, current guidelines did not provide specific recommendations for the use of ICDs/CRTs in patients with CKD.
The protective effect of ICDs and CRTs in patients with CKD remains controversial despite active use. The decision to implant ICDs/CRTs in CKD patients varies significantly across physicians and jurisdictions [2] .
The aim of this meta-analysis is to explore the association between ICD/CRT and survival in CKD patients (including both non-dialysis-dependent and dialysis-dependent patients).
Methods

Literature search and data sources
An electronic literature search was performed by three investigators in accordance with the recommendations of Cochrane Collaboration using PubMed until August 1, 2016. Two sets of different search terms were used to ensure adequate and comprehensive literature review: Neither language nor demographic restrictions were applied. All references from papers obtained through the databases were reviewed manually.
Study selection and quality assessment
The inclusion was limited to studies which are (1) controlled studies that compared the outcomes of interest stratified by the presence of ICD, CRT, or none in patients with chronic kidney disease with a standard indication for ICD or CRT, (2) included adult population > 18 years old, and (3) provided comprehensive data on outcomes of interest. We excluded studies that did not provide data on all-cause mortality (primary outcome). We included only full papers and excluded abstracts/reports that did not provide full data about the outcomes of interest. The selection of studies was reviewed and assessed independently by two assessors (MS, YZ).
We used the Newcastle-Ottawa Scale to further assess the quality of the observational studies. Studies were judged on three broad perspectives: (1) selection of the study groups, (2) comparability of the groups, and (3) ascertainment of either the exposure or outcomes of interest for case-control or cohort studies, respectively.
Outcomes of interest
The following outcomes were considered relevant measures to compare the studied groups: (1) primary outcome including all-cause mortality, defined as all deaths that were reported in the studies from cardiovascular and non-cardiovascular causes. (2) Secondary outcome including all-cause hospitalization as reported in the included studies.
Data extraction
Three reviewers (NY, AY, WQ) extracted the data from included studies. The final data worksheet was reviewed independently by two reviewers (MS, YZ). Disagreements were resolved by discussion and, when necessary, in consultation with other authors.
Primary authors of potential studies lacking the rate of allcause mortality were contacted to obtain the data of interest; otherwise, the study would be excluded.
Statistics
The software package RevMan (version 5) provided by the Cochrane Collaboration was used for combining outcomes from the individual studies and statistical analysis. Outcomes were pooled using a random effects model described by DerSimonian and Laird [11] . Summary estimates and 95% confidence interval (CI) were reported for dichotomous variables as odds ratio (OR). The heterogeneity between studies was assessed using Cochrane's χ 2 and I
2
. An I 2 > 50% was considered to represent significant heterogeneity. Statistical significance was set as P < 0.05. Weighted means were calculated for the variable baseline characteristics whenever possible. Otherwise, the medians were captured with range or interquartile range as reported in the individual studies.
Subgroup analysis was also performed and reported separately [12] . 
Summary of the studies
The literature search resulted in 1458 studies (1151 from electronic database (PubMed) and 307 from other resources including manual web searches, references lists, and review articles). As a result of the literature review and personal communications, we identified 11 studies (including 21,136 patients) that met all applied inclusion criteria for this meta-analysis [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . All studies were retrospective controlled studies or retrospective analyses of prospective studies. No studies were prospective or randomized. The information relevant to the literature search is shown in Fig. 1 . We included seven studies that compared ICD vs. no ICD [16] [17] [18] [20] [21] [22] [23] and four studies that compared CRT vs. ICD [13] [14] [15] 19] . The mean follow-up period was variable and reported differently among the papers. Both dialysis-and non-dialysis-dependent CKD patients were included. Also, studies included mixed patient population with primary and secondary indication for ICD/CRT.
ICD vs. no ICD
We included seven studies that compared ICD vs. no ICD with a total of 8041 patients (ICD 1419 patients and no ICD 6622 patients) ( Table 1) . Baseline demographics and clinical characteristics were similar between both groups. There were no significant differences between ICD and no ICD groups in age: (mean ± SD) 71 ± 3 vs. 72 ± 3, P = 0.50; male gender 65% vs. 50%, P = 0.36; coronary artery disease 59% vs. 53%, P = 0.82; heart failure 61% vs. 57%, P = 0.98; or left ventricular ejection fraction: (mean ± SD) 27 ± 3 vs. 27 ± 2, P = 0.83 (Table 2 ).
All-cause mortality was significantly lower in the ICD group in comparison to that in the no ICD group (OR 0.66 (95% CI 0.45; 0.98), P = 0.04). Significant heterogeneity was noted for that comparison (I 2 = 82%, P < 0.001) (Fig. 2) .
A subgroup analysis was performed including the studies that reported the primary outcome among dialysis-only patients. All-cause mortality was significantly lower in the ICD group in comparison to that in the no ICD group among dialysis-only patients (OR 0.49 (95% CI 0.38; 0.64), P < 0.001). No significant heterogeneity was noted for that comparison (I 2 = 20%, P < 0.001) (Fig. 3 ).
CRT vs. ICD
We identified four studies that compared CRT vs. ICD with a total of 13,095 patients (CRT 10,838 patients and ICD 2257 patients) (Table 3) . Baseline demographics and clinical characteristics were similar between both groups. There were no significant differences between CRT and ICD groups in age: (mean ± SD) 75 ± 4 vs. 72 ± 6, P = 0.96; male gender 67% vs. 76%, P = 0.92; coronary artery disease 67% vs. 77%, P = 0.19; or left ventricular ejection fraction: (mean ± SD) 23 ± 1 vs. 24 ± 3, P = 0.36 (Table 4 ). All-cause mortality was significantly lower in the CRT group in comparison to that in the ICD group (OR 0.73 (95% CI 0.57; 0.92), P = 0.01). No significant heterogeneity was noted for that comparison (I 2 = 31%, P = 0.23) (Fig. 4 ).
There were only two studies that reported all-cause hospitalization with no significant differences between CRT and ICD groups (OR 0.86, 95% CI 0.52; 1.43, P = 0.57). 
Discussion
Clinical implication
Our meta-analysis has demonstrated the following main findings: (1) the use of ICD is associated with lower all-cause mortality in CKD patients, and similar protective effect is observed among dialysis-only patients; (2) CRT has shown lower all-cause mortality in CKD patients in comparison to ICD but without clear impact on all-cause hospitalization. The decision of implanting ICD or CRT in patients with CKD especially among those on dialysis is challenging, as the prevalence of non-arrhythmic deaths is significant. More than 50% of mortality in dialysis patients is due to noncardiovascular causes (non-arrhythmic), where infections and malignancies are the most prominent causes of death [1] . Nevertheless, our findings support the survival benefit of ICDs and CRTs in CKD patients with a standard indication. So far, this is the largest meta-analysis to assess the role of ICDs and CRTs in CKD patients. There are a few metaanalyses in the current literature that included a smaller number of studies and smaller/different patient population with conflicting results. More so, our meta-analysis is the first and largest to compare CRTs to ICDs in CKD patients [24] [25] [26] .
ICD vs. no ICD
Our data on the beneficial use of ICDs in CKD patients is important especially in the presence of conflicting studies. Some retrospective studies did not support the use of ICD in CKD patients, representing renal insufficiency as an independent predictor of mortality among ICD patients [27] . This was explained by the high incidence of non-arrhythmic deaths, increased sympathetic nervous system activity, arrhythmias refractory to ICD therapy, or failed ICD therapies due to elevated defibrillation thresholds [27, 28] . More so, patients with ESRD receiving ICDs have an increased risk of developing procedure-related complications with up to 21.9% risk of bleeding and 12.5% risk of device-related infections [29] .
On the other hand, the benefits of ICDs in CKD were evident in several studies [17, 20, 21] . The higher incidence of ventricular arrhythmias (SCD) and coronary artery disease, the common finding of severe left ventricular systolic dysfunction (15% of hemodialysis patients), and the predominant rate of heart failure along with multiple cardiovascular comorbidities among CKD patients (especially with ESRD) warrant the use of ICDs as shown in our study [18] . In fact, this survival benefit should mitigate the concerning higher procedural risks involved with such implantations. Fig. 3 Forest plots of the individual and combined rates of all-cause mortality in ICD vs. no ICD in dialysis only patients Severe CKD patients may perhaps be too sick to benefit from ICDs, given the competing causes of death that ICD itself may not mitigate [30] . However, our results showed a potential protective effect of ICDs among this patient population, likely related to the high rate of arrhythmic events (SCD) particularly seen in patients with ESRD.
CRT vs. ICD
Interestingly, among our CKD patients, CRTs showed better survival benefits in comparison to ICDs. The positive effect of CRTs in CKD is well established. CRTs have favorable effect on mortality related to heart failure, which is not achievable with ICDs. More so, CRTs improve kidney function (increasing GFR and reducing blood urea nitrogen) by improving the LV function hence kidney perfusion [31] . Eisen et al. demonstrated that GFR in ICD patients decreases over time (marginally statistically significant) as opposed to CRT-D patients with CKD [14] . Effective LV reverse modeling in CRT patients with systolic heart failure and renal insufficiency plays an important role in preserving the renal function regardless of the degree of baseline renal insufficiency providing favorable long-term morbidity and mortality [32] . Finally, CRT is known to decrease sympathetic nerve activity hence decrease the burden of ventricular arrhythmias and arrhythmic deaths [33] . Although subgroup analysis according to GFR was not possible in our analysis, in a large study by Friedman et al., CRT-D use was associated with a significantly lower risk of HF hospitalization or death in patients with advanced CKD [15] . The positive effect of CRTs seen in our study in comparison to ICD highlights the important role of the resynchronization process over the defibrillation element. This should warrant further attention to consider CRT-P in this patient population.
Operators usually would favor ICDs in CKD patient (less hardware and shorter procedure time); however, in light of our analysis, CKD patients should be offered CRTs, if indicated, with significant benefits that outweigh extra risks involved with such procedure.
Limitations
Some studies were of limited quality, given their retrospective and single-center designs. There were not any RCTs included in this analysis, which limits the quality of this analysis. The discrepancy of follow-up periods among the studies could affect the outcomes. There were noticeable differences between the studies regarding reporting and definition of outcomes. The patient population in the included studies had mixed (primary and secondary) indication for ICD/CRT and a wide range of CKD level (dialysis to GFR > 60), which could explain the significant heterogeneity noted with some of the outcomes. We could not perform comprehensive subgroup analysis because of the limited data.
Conclusion
The use of ICDs is associated with lower all-cause mortality in observational studies of CKD patients, and similar protective effect is observed among dialysis-only patients despite the compelling comorbidities that are involved. CRTs showed an even lower all-cause mortality in CKD patients in comparison to ICDs. A randomized controlled trial is required to definitively define the role of ICDs/CRTs in CKD patients.
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